Quinlock (repretenib) approved for GIST – pro
The FDA recently approved Deciphera Pharmaceuticals’ ripretinib (Qinlock), the first drug for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST). The medication is only indicated for adults who have previously received treatment with 3 or more kinase inhibitor therapies, including imatinib.
Schneeweiss M, Peter B, Bibi S, et al. (May 2018). “The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis”. Haematologica. 103 (5): 799809.
John Nemunaitis et al, Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib FUTURE ONCOLOGYVOL. 16, NO. 1, 2019